A ranar 16 ga Yuli, wata babbar mujallar kasa da kasa mai suna Nature Medicine ta buga bayanan bincike kan SHR-A1904, wani maganin rigakafi da maganin rigakafi (ADC) wanda ke nufin claudin 18.2 (CLDN18.2), don magance cutar kansar ciki ko kuma cutar kansar gastroesophageal junction (GC/GEJC). Masu binciken sun gudanar da wani gwaji na farko a cikin mutum, mai matakai uku, na gwaji na asibiti na Mataki na 1 don tantance ingancin SHR-A1904 a cikin marasa lafiya 95 da aka yi wa magani a baya da ke dauke da cutar kansar G/GEJ mai dauke da CLDN18.2-positive.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Claudin-18 isoform 2 (CLDN18.2), wani sinadari mai matsewa wanda aka bayyana a cikin epithelium na ciki wanda ba shi da lahani kuma wanda aka fallasa a saman ƙwayoyin ƙari yayin canjin cutar kansa, wani abu ne mai kyau da za a yi la'akari da shi wajen magance cutar kansar ciki da ta hanji (G/GEJ). SHR-A1904 wani sinadari ne na rigakafi wanda ya ƙunshi ƙwayoyin cuta na CLDN18.2 da ke niyya, wani sinadari mai hana DNA topoisomerase I da kuma wani sinadari mai tushen peptide da za a iya cirewa.
A matakin ƙaruwar allurai (0.6–8.0 mg kg−1), an lura da guba mai iyakance allurai a cikin marasa lafiya biyu a 4.8 mg kg−1 (matsayi na 3 febrile neutropenia da matakin 3 ya karu da bilirubin jini) da kuma a cikin majiyyaci ɗaya a 6.0 mg kg−1 (matsayi na 3 na mucosal mucosal). Ba a kai matsakaicin adadin da aka yarda da shi ba, kuma an zaɓi 6.0 mg kg−1 da 8.0 mg kg−1 don faɗaɗa pharmacokinetic da inganci. Abubuwan da suka faru na gaggawa na magani sun faru a cikin dukkan marasa lafiya 95, galibi anemia (72 (75.8%)), tashin zuciya (64 (67.4%)), hypoalbuminemia (61 (64.2%)) da raguwar adadin fararen ƙwayoyin jini (56 (58.9%)). Bugu da ƙari, marasa lafiya 59 (62.1%) sun fuskanci mummunan sakamako na maki na 3 ko sama da haka na magani. Ba a bayar da rahoton mutuwar da ta shafi magani ba. Daga cikin marasa lafiya da ake kimantawa game da amsawar, adadin amsawar da aka tabbatar shine 24.2% (95% tazara amincewa (CI), 11.1–42.3) a 6.0 mg kg−1 da 25.0% (95% CI, 12.1–42.2) a 8.0 mg kg−1. Matsakaicin rayuwa ba tare da ci gaba ba shine watanni 5.6 (95% CI, 3.0–6.9) a 6.0 mg kg−1 da watanni 5.8 (95% CI, 3.0–8.6) a 8.0 mg kg−1. A ƙarshe, SHR-A1904 ya nuna yanayin aminci mai sarrafawa da ƙarfafa aikin hana ƙari ga marasa lafiya da ke fama da cutar kansa ta CLDN18.2-positive G/GEJ, wanda ke buƙatar ƙarin bincike.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Lokacin Saƙo: Yuli-24-2025